What's new at DZP?

Current projects.

DZP coordinates three-part transaction with GSK and Novartis

26.05.2015

Autorzy:
Michał Czarnuch
Dr Bartosz Marcinkowski
Dr hab. Marcin Matczak

DZP advised GlaxoSmithKline in a three-part conditional transaction with Novartis AG in the following areas: health care means (Consumer Healthcare), vaccinations and cancer medicines. Both parties to the transaction – GlaxoSmithKline and Novartis, are international leaders – pharmaceutical manufacturers and investors.

As of now, GSK and Novartis will cooperate on the OTC medicine market thus becoming a global leader in this area. Concurrently, GSK took over from Novartis the vaccination business (apart from influenza vaccinations), and Novartis purchased from GSK the cancer portfolio and the related research and development. The transaction covered 52 jurisdictions.

The DZP lawyers who advised GSK were Marcin Matczak and Michał Czarnuch from the Life Sciences Practice as well as Bartosz Marcinkowski and Marcin Kuliński from the Corporate and M&A Practice.